Adverse events associated with bone-directed therapies in patients with cancer
MA Jara, J Varghese, MI Hu - Bone, 2022 - Elsevier
Bone metastatic disease may lead to serious adverse events in patients with cancer. Bone-
directed therapies, including bisphosphonates such as pamidronate and zoledronic acid …
directed therapies, including bisphosphonates such as pamidronate and zoledronic acid …
[HTML][HTML] Is the use of bisphosphonates putting horses at risk? An osteoclast perspective
FB Vergara-Hernandez, BD Nielsen, AC Colbath - Animals, 2022 - mdpi.com
Simple Summary Bisphosphonates are a group of drugs that intervene in the bone
resorption process, producing cellular death of osteoclasts. These drugs are used for …
resorption process, producing cellular death of osteoclasts. These drugs are used for …
Hip fractures: diagnosis and management
JD Schroeder, SP Turner, E Buck - American Family Physician, 2022 - aafp.org
Hip Fractures: Diagnosis and Management | AAFP search close The website will be down at
times for maintenance from 8:00 am CT Saturday, March 2 through 10:00 am CT Sunday, March …
times for maintenance from 8:00 am CT Saturday, March 2 through 10:00 am CT Sunday, March …
Guideline no. 422g: menopause and osteoporosis
Objective Provide strategies for improving the care of perimenopausal and postmenopausal
women based on the most recent published evidence. Target Population Perimenopausal …
women based on the most recent published evidence. Target Population Perimenopausal …
[HTML][HTML] Current concepts in the management of bisphosphonate associated atypical femoral fractures
B Rudran, J Super, R Jandoo, V Babu… - World Journal of …, 2021 - ncbi.nlm.nih.gov
Bisphosphonates are a class of drugs used as the mainstay of treatment for osteoporosis.
Bisphosphonates function by binding to hydroxyapatite, and subsequently targeting …
Bisphosphonates function by binding to hydroxyapatite, and subsequently targeting …
Osteoporosis treatment rate following hip fracture in a community hospital
AA Khan, H AbuAlrob, F Tariq, M Tauqir, P Zalzal… - Archives of …, 2021 - Springer
Treatment rates for osteoporosis after a major osteoporotic fracture are unacceptably low.
We evaluate the effectiveness of an ortho-geriatric team (OGT) in initiating pharmacologic …
We evaluate the effectiveness of an ortho-geriatric team (OGT) in initiating pharmacologic …
[HTML][HTML] Atypical Femoral Fracture in Hypophosphatasia: A Systematic Review
N Charoenngam, J Thongpiya… - International Journal of …, 2023 - hindawi.com
Objective. To summarize the characteristics of all reported patients with hypophosphatasia
(HPP) who sustained atypical femoral fracture (AFF) and identify all available evidence to …
(HPP) who sustained atypical femoral fracture (AFF) and identify all available evidence to …
[HTML][HTML] Role of bone-modifying agents in advanced cancer
DN Desautels, CH Harlos… - Annals of Palliative …, 2020 - apm.amegroups.org
Bone lesions from metastatic solid tumors and multiple myeloma (MM) represent an
important source of morbidity in patients with incurable malignancies. Dysregulation of …
important source of morbidity in patients with incurable malignancies. Dysregulation of …
[HTML][HTML] Recommendations on the post-acute management of the osteoporotic fracture-Patients with “very-high” Re-fracture risk
Osteoporosis is a systemic skeletal disease where there is low bone mass and deterioration
of bone microarchitecture, leading to an increased risk of a fragility fracture. The aim of this …
of bone microarchitecture, leading to an increased risk of a fragility fracture. The aim of this …
Mortality risk after atypical femoral fracture: a systematic review and meta-analysis
Objective To summarize all available data using systematic review and meta-analysis to
estimate the 1-year mortality risk after atypical femoral fracture (AFF) and risk ratio of …
estimate the 1-year mortality risk after atypical femoral fracture (AFF) and risk ratio of …